Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:DNA - US37611X2099 - Common Stock

9.4 USD
+0.15 (+1.62%)
Last: 12/8/2025, 8:04:21 PM
9.54 USD
+0.14 (+1.49%)
After Hours: 12/8/2025, 8:04:21 PM
Fundamental Rating

3

DNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for DNA as it has an excellent financial health rating, but there are worries on the profitability. DNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNA had negative earnings in the past year.
In the past year DNA has reported a negative cash flow from operations.
DNA had negative earnings in each of the past 5 years.
In the past 5 years DNA always reported negative operating cash flow.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -500M -1B -1.5B -2B

1.2 Ratios

The Return On Assets of DNA (-28.55%) is worse than 73.68% of its industry peers.
DNA's Return On Equity of -60.66% is on the low side compared to the rest of the industry. DNA is outperformed by 75.44% of its industry peers.
Industry RankSector Rank
ROA -28.55%
ROE -60.66%
ROIC N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of DNA (72.71%) is better than 96.49% of its industry peers.
In the last couple of years the Gross Margin of DNA has declined.
DNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DNA has been increased compared to 1 year ago.
The number of shares outstanding for DNA has been reduced compared to 5 years ago.
DNA has a better debt/assets ratio than last year.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of -7.03, we must say that DNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.03, DNA is not doing good in the industry: 89.47% of the companies in the same industry are doing better.
There is no outstanding debt for DNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.03
ROIC/WACCN/A
WACC10.42%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.39 indicates that DNA has no problem at all paying its short term obligations.
DNA's Current ratio of 4.39 is fine compared to the rest of the industry. DNA outperforms 71.93% of its industry peers.
A Quick Ratio of 4.39 indicates that DNA has no problem at all paying its short term obligations.
DNA's Quick ratio of 4.39 is fine compared to the rest of the industry. DNA outperforms 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.06% over the past year.
Looking at the last year, DNA shows a very negative growth in Revenue. The Revenue has decreased by -17.13% in the last year.
Measured over the past years, DNA shows a very strong growth in Revenue. The Revenue has been growing by 33.17% on average per year.
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%

3.2 Future

Based on estimates for the next years, DNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.86% on average per year.
DNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.14% yearly.
EPS Next Y36.23%
EPS Next 2Y22.25%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue Next Year-23.62%
Revenue Next 2Y-9.48%
Revenue Next 3Y2%
Revenue Next 5Y10.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNA. In the last year negative earnings were reported.
Also next year DNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as DNA's earnings are expected to grow with 15.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.25%
EPS Next 3Y15.82%

More info and screens

0

5. Dividend

5.1 Amount

DNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (12/8/2025, 8:04:21 PM)

After market: 9.54 +0.14 (+1.49%)

9.4

+0.15 (+1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners63.32%
Inst Owner Change-9%
Ins Owners3.44%
Ins Owner Change0.03%
Market Cap541.35M
Revenue(TTM)180.61M
Net Income(TTM)-339.55M
Analysts41.82
Price Target10.88 (15.74%)
Short Float %15.24%
Short Ratio4.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.35%
Min EPS beat(2)-15.78%
Max EPS beat(2)30.48%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-15.78%
Max EPS beat(4)30.48%
EPS beat(8)5
Avg EPS beat(8)9.77%
EPS beat(12)6
Avg EPS beat(12)1.99%
EPS beat(16)6
Avg EPS beat(16)-240.57%
Revenue beat(2)1
Avg Revenue beat(2)8.5%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)18.03%
Revenue beat(4)2
Avg Revenue beat(4)9.57%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)23.63%
Revenue beat(8)4
Avg Revenue beat(8)15.72%
Revenue beat(12)8
Avg Revenue beat(12)14.38%
Revenue beat(16)12
Avg Revenue beat(16)23.68%
PT rev (1m)-11.11%
PT rev (3m)-5.88%
EPS NQ rev (1m)-7.09%
EPS NQ rev (3m)-14.96%
EPS NY rev (1m)-7.46%
EPS NY rev (3m)-6.51%
Revenue NQ rev (1m)-6.01%
Revenue NQ rev (3m)-7.65%
Revenue NY rev (1m)-1.76%
Revenue NY rev (3m)-1.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-6.23
EYN/A
EPS(NY)-4.52
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS3.14
BVpS9.72
TBVpS8.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.55%
ROE -60.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.71%
FCFM N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.04%
Cap/Sales 11.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z -7.03
F-Score4
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
EPS Next Y36.23%
EPS Next 2Y22.25%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%
Revenue Next Year-23.62%
Revenue Next 2Y-9.48%
Revenue Next 3Y2%
Revenue Next 5Y10.14%
EBIT growth 1Y19.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.58%
EBIT Next 3Y26.55%
EBIT Next 5Y15.81%
FCF growth 1Y53.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.54%
OCF growth 3YN/A
OCF growth 5YN/A

GINKGO BIOWORKS HOLDINGS INC / DNA FAQ

What is the ChartMill fundamental rating of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DNA.


What is the valuation status of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

ChartMill assigns a valuation rating of 0 / 10 to GINKGO BIOWORKS HOLDINGS INC (DNA). This can be considered as Overvalued.


How profitable is GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for GINKGO BIOWORKS HOLDINGS INC?

The Earnings per Share (EPS) of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to grow by 36.23% in the next year.